<DOC>
	<DOCNO>NCT02318914</DOCNO>
	<brief_summary>The study evaluate long-term safety gevokizumab treat active PG ulcer</brief_summary>
	<brief_title>A 2-Year , Open-Label , Safety Extension Study Gevokizumab Subjects With Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>Individuals participate previous study gevokizumab PG A clinical diagnosis classic pyoderma gangrenosum Contraceptive measure adequate prevent pregnancy study Clinical evidence acutely infected pyoderma gangrenosum History allergic anaphylactic reaction monoclonal antibody History recurrent chronic systemic infection Female subject pregnant , plan become pregnant , recently deliver , breastfeed Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Classic Pyoderma Gangrenosum</keyword>
</DOC>